Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 30, 2012

View Archived Issues

New orally bioavailable renin inhibitor developed by Daiichi Sankyo

Candidate analgesic releases pregabalin and nitric oxide

Novel candidate drug for heart failure completes phase I trial

Nucynta ER approved for new indication in U.S.

Pfizer presents first-in-human data on new PDE2A inhibitor for schizophrenia

Zytiga sNDA receives priority review status

Proacta obtains FDA clearance for clinical PR-610 study

New drug candidate shows potential as treatment for malaria

Phase III lomitapide study reaches week 78

Lilly discontinues phase III development of schizophrenia drug

Confirmatory U.S. phase III trial begins for Scenesse

Treatment begins in CUPID study

Novel potential COPD therapies developed at GlaxoSmithKline

Idenix Pharmaceuticals designs new candidate hepatitis C drugs

Novartis discloses novel CDK9 inhibitors

Novel BCR-ABL inhibitors synthesized in China

Jinan Saiwen Pharmaceutical Technology reports new MEK inhibitors

Protalex reports encouraging results from PRTX-100 trial

Pfizer announces new launch of axitinib tablets

New data presented on Xiaflex in Peyronie's disease

Eisai seeks Japanese approval for antiepileptic agent

Bayer HealthCare receives European label extension

FDA approves Teva drug for chemotherapy-induced neutropenia

Kyowa Hakko Kirin suspends enrollment in phase III NSCLC study

Noven files NDA for therapy for menopausal vasomotor symptoms

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...